Martin Babler, Alumis CEO
Alumis closes a $259M Series C to back its TYK2, flirts with talk about an IPO
As it prepares to launch Phase III studies of its TYK2 inhibitor, immunology startup Alumis has raised a $259 million Series C round that will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
